Locked nucleic acid (LNA): A modern approach to cancer diagnosis and treatment

Cancer is responsible for about one in six deaths in the world. Conventional cancer treatments like chemotherapy, radiotherapy, and surgery are associated with drug poisoning and poor prognosis. Thanks to advances in RNA delivery and target selection, new cancer medicines are now conceivable to impr...

Full description

Saved in:
Bibliographic Details
Published inExperimental cell research Vol. 423; no. 1; p. 113442
Main Authors Kamali, Mohammad Javad, Salehi, Mohammad, Fatemi, Somayeh, Moradi, Fereshteh, Khoshghiafeh, Azin, Ahmadifard, Mohamadreza
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.02.2023
Subjects
Online AccessGet full text
ISSN0014-4827
1090-2422
1090-2422
DOI10.1016/j.yexcr.2022.113442

Cover

More Information
Summary:Cancer is responsible for about one in six deaths in the world. Conventional cancer treatments like chemotherapy, radiotherapy, and surgery are associated with drug poisoning and poor prognosis. Thanks to advances in RNA delivery and target selection, new cancer medicines are now conceivable to improve the quality of life and extend the lives of cancer patients. Antisense oligonucleotides (ASOs) and siRNAs are the most important tools in RNA therapies. Locked Nucleic Acids (LNAs) are one of the newest RNA analogs, exhibiting more affinity to binding, sequence specificity, thermal stability, and nuclease resistance due to their unique properties. Assays using LNA are also used in molecular diagnostic methods and provide accurate and rapid mutation detection that improves specificity and sensitivity. This study aims to review the special properties of LNA oligonucleotides that make them safe and effective antisense drugs for cancer treatment by controlling gene expression. Following that, we go over all of the molecular detection methods and cancer treatment antisense tactics that are possible with LNA technology.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0014-4827
1090-2422
1090-2422
DOI:10.1016/j.yexcr.2022.113442